显微外科与放射外科治疗三叉神经痛安全性和有效性的Meta分析
该系统评价与Meta分析检索2005至2015年PubMed文献,纳入53项研究共13805例患者,比较微血管减压术(MVD)与放射外科治疗(RS)的疼痛控制、并发症和复发。MVD初始成功率和末次随访(>5年)成功率均高于RS,36个月时复发中位百分比MVD低于RS,而面部感觉异常RS高于MVD。
要点
- MVD初始成功率86.9%高于RS的71.1%(P<0.0001)。
- 末次随访(>5年)成功率MVD 84%高于RS 63.8%(P=0.036)。
- 36个月复发中位百分比MVD 11%低于RS 25%(P=0.0015)。
核心结论
- MVD是年轻且无合并症患者有效的首选治疗选择。
- 对于手术风险较高的患者,可建议将RS作为一线治疗。
研究设计与样本
- 检索PubMed 2005至2015年关于MVD或RS治疗后疼痛控制、并发症和复发的研究,遵循PRISMA指南。
- 因缺乏随机研究,统计分析聚焦于队列临床试验,采用t检验和加权平均值分析差异。
- 共纳入53项研究(13805例患者),包括11项前瞻性研究和42项回顾性研究。
主要发现
- 初始成功率RS为71.1%,MVD为86.9%(P<0.0001)。
- 末次随访(>5年)成功率RS降至63.8%,MVD为84%(P=0.036)。
- 干预后36个月复发中位百分比MVD为11%,RS为25%(P=0.0015)。
- 无复发生存间期MVD与RS相似(30.45个月 vs 30.55个月;P=0.987)。
- 听力损失发生率MVD与RS无显著差异(1.51% vs 0.74%;P=0.21);面部感觉异常RS报告更频繁(2.3% vs 28.8%;P=0.02)。
临床怎么用
- 作者认为MVD是年轻且无合并症患者有效的首选治疗选择。
- 作者建议对手术风险较高的患者可考虑将RS作为一线治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Classic trigeminal neuralgia is often treated pharmacologically first. However, microvascular decompression (MVD) or radiosurgical treatment (RS) can render medication unnecessary. Objective appraisals of the 2 treatment modalities are scarce. OBJECTIVE: To compare the evidence regarding safety and efficiency of MVD and RS. METHODS: We searched PubMed for studies describing pain control, complications, and recurrences after MVD or RS between 2005 and 2015. Because randomized studies are lacking, we focused the statistical analysis on cohort clinical trials. Differences in outcome after treatment with either MVD or RS were analyzed using t tests and weighted averages. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. RESULTS: Fifty-three studies (13,805 patients, in 11 prospective and 42 retrospective studies) were analyzed. Initial success rates were 71.1% for RS and 86.9% for MVD (P < 0.0001). At last follow-up (>5 years after intervention), success rates decreased to 63.8% for RS versus 84% for MVD (P = 0.036). Thirty-six months after the intervention, median percentage of recurrence was 11% for MVD and 25% for RS (P = 0.0015). The length of recurrence-free intervals was similar for MVD and RS (30.45 vs. 30.55 months; P = 0.987). There was no significant difference between the incidence of hearing loss after MVD and RS (1.51% vs. 0.74%; P = 0.21). Facial dysesthesia was reported more frequently after radiosurgery (2.3% vs. 28.8%; P = 0.02). CONCLUSIONS: MVD is a valid first-line treatment option for young patients free of comorbidities. First-line RS can be advised in patients with a higher surgical risk.
引用
- Gubian A, Rosahl SK. Meta-Analysis on Safety and Efficacy of Microsurgical and Radiosurgical Treatment of Trigeminal Neuralgia. World Neurosurg. 2017. PMID: 28435111. doi:10.1016/j.wneu.2017.04.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。